IL7 and B-cell non-Hodgkin lymphoma: recently introduced a TGF-β-targeting switch receptor that can change TGF-β signaling into IL-7 signaling, and expression of the receptor improved tumor control in the CAR-T-based B-cell lymphoma suppression model (144).